Repligen (NASDAQ:RGEN) Lowered to “Sell” Rating by StockNews.com

StockNews.com lowered shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a report issued on Thursday.

Other analysts have also recently issued research reports about the stock. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday. They issued a “hold” rating and a $165.00 price objective for the company. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday. They issued a “hold” rating and a $165.00 price target for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $185.20.

Repligen Price Performance

NASDAQ:RGEN opened at $146.54 on Thursday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The stock’s 50-day moving average price is $144.07 and its 200-day moving average price is $141.81. The stock has a market capitalization of $8.21 billion, a PE ratio of -396.04, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.23 earnings per share. As a group, equities analysts expect that Repligen will post 1.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently modified their holdings of the company. Andra AP fonden purchased a new stake in Repligen during the second quarter worth about $25,000. UMB Bank n.a. grew its stake in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares in the last quarter. Blue Trust Inc. increased its position in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the period. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the third quarter valued at $37,000. Finally, International Assets Investment Management LLC purchased a new position in Repligen in the second quarter valued at $33,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.